Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.20.2
Basis of Presentation and Significant Accounting Policies (Details)
3 Months Ended 9 Months Ended
Jan. 07, 2020
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
USD ($)
Apr. 23, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Basis of Presentation and Significant Accounting Policies                    
Accumulated deficit   $ 124,195,893   $ 124,195,893     $ 104,597,748      
Net loss   8,916,433 $ 6,330,913 19,826,671 $ 17,094,899          
Cash, cash equivalents and short term investments   117,300,000   117,300,000            
Derivative warrant liability   60,915   $ 60,915            
Number of operating segments | segment       1            
Goodwill                    
Goodwill impairment loss   0 $ 737,000 $ 0 $ 737,000          
Revenue Recognition                    
Allowable expenses incurred under NIH grant   100,000   100,000            
Revenue recognized under NIH grant   $ 302,020   $ 302,020            
Maximum                    
Basis of Presentation and Significant Accounting Policies                    
Aggregate public offering price           $ 150,000,000        
Revenue Recognition                    
Amount awarded from NIH grant $ 224,713                  
At The Market Offerings | Maximum                    
Basis of Presentation and Significant Accounting Policies                    
Percentage of commission fees to sales agent           3.00%        
Pelican Therapeutics, Inc.                    
Basis of Presentation and Significant Accounting Policies                    
Ownership interest in subsidiary   85.00%   85.00%     85.00%      
Pelican Therapeutics, Inc.                    
Basis of Presentation and Significant Accounting Policies                    
Percentage of voting interests acquired in acquisition               85.00% 80.00% 80.00%